ArticleFrontiers in aging neuroscience2025
The differential expression profiles of miRNA in serum-derived exosomes and its potential role in age-related hearing loss.
Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to characterize serum exosomal miRNA profiles from patients with age-related hearing loss (ARHL) to identify key pathogenesis-related miRNAs for ARHL. Methods: Peripheral venous blood samples were collected from patients with ARHL and elderly controls, and exosomes were isolated from serum of each subject. Then, the isolated exosomes were systematically identified by nanoparticle tracking analysis (NTA), transmission electron microscopy (TEM) and western blot. Subsequently, the isolated exosomes were submitted for miRNA sequencing and a series of bioinformatics analysis. Ultimately, four key DE-miRNAs, namely hsa-miR-100-5p, hsa-miR-23b-3p, hsa-miR-373-3p, and hsa-miR-27b-3p, were verified using quantitative real-time polymerase chain reaction (RT-qPCR). Results: NTA, TEM and western blot confirmed exosomes were successfully isolated. After sequencing, 22 differential expressed miRNAs (6 up-regulation and 16 down-regulation) were identified between the exosomes from ARHL and controls, and then collectively identified 17,451 predicted target genes and 15,863 experimentally validated target genes. Gene Ontology enrichment analysis revealed that the target genes were significantly associated with "regulation of neuron projection development," "sensory system development," "proteasome-mediated ubiquitin-dependent protein catabolism," and "ubiquitin-like protein ligase binding." Kyoto Encyclopedia of Genes and Genomes (KEGG) showed the target genes were significantly enriched in "PI3K-Akt signaling pathway," "MAPK signaling pathway," "cellular senescence," "autophagy," "mTOR signaling pathway," "ubiquitin-mediated proteolysis," and "signaling pathways regulating stem cell pluripotency." Additionally, the Reactome analysis highlighted the involvement of "MAPK family signaling cascades," "negative regulation of the PI3K/AKT network," and "antigen processing: ubiquitination and proteasome degradation." Disease Ontology further demonstrated significant enrichment of target genes in neurological disorders. RT-qPCR showed hsa-miR-100-5p and hsa-miR-23b-3p exhibited markedly decreased levels, while hsa-miR-373-3p and hsa-miR-27b-3p were significantly up-regulated in ARHL, which were consistent with sequencing results, confirming a high relatively reliability of the sequencing results. Conclusion: Ubiquitination modification, autophagy process, cellular senescence and nervous system regulation may jointly contribute to the core molecular mechanism of ARHL. The hsa-miR-100-5p, hsa-miR-23b-3p, hsa-miR-373-3p, and hsa-miR-27b-3p may preliminarily act as key regulatory factors to participate in the pathophysiological process of ARHL, providing exploratory evidence for their potential application value as molecular markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.